Johnson & Johnson files application to test its COVID vaccine on adolescents; all you need to know

-

Johnson & Johnson Friday said it has submitted an application to the Indian drug regulator to conduct a study of its COVID-19 vaccine in adolescents aged 12-17 years.

The US-based pharmaceutical company noted that it is committed to facilitating global equitable access to its COVID-19 vaccine and recognise the unmet needs of children.

"On 17 August, 2021, we submitted an application to the Central Drugs Standard Control Organisation (CDSCO) to conduct a study of the Johnson & Johnson COVID-19 vaccine in India in adolescents aged 12-17 years," a J&J India spokesperson said in a statement.

Why is this relevant?

If granted the due approval, this will be the third vaccine candidate to be tested on adolescents in India. However, Indian manufacturers Bharat Biotech and Zydus Cadila have already beat J&J in that race.

Earlier today, Zydus Cadila's ZyCov-D was granted emergency use approval for vaccinating those aged 12 and above. Bharat Biotech's Covaxin, on the other hand is also in the final stages of its clinical trial for children as young as 2 years of age, and has shown 'promising results'. It expects to be ready for approval and roll out by next month.

To ultimately achieve herd immunity, it is imperative that COVID-19 vaccine clinical trials continue to move forward not only in adults but in the adolescent and infant population as well.

Furthermore, J&J vaccine's single-dose regimen and a higher tolerance for temperature could also boost the availability of the shots even in remote parts of the country. This gains in significance given that the country has recently been criticised for its slow pace of vaccination.

Is J&J vaccine also available for adults?

Earlier this month, the government had given Emergency Use approval to J&J's single-dose COVID-19 vaccine in India.

While announcing the approval, Union Health Minister Mansukh Mandaviya had said the approval would further boost the country's collective fight against the novel coronavirus infection.

The six vaccines granted Emergency Use Authorisation in India are Serum Institute's Covishield, Bharat Biotech's Covaxin, Russia's Sputnik V, Zydus Cadila's ZyCov-D, Moderna, and J&J.

How is it different?

Unlike its US counterparts, Moderna and Pfizer vaccines, the Johnson & Johnson vaccine does not use messenger RNA (mRNA) to help the body build its defenses against the virus. Instead, it is an adenovector vaccine like the Oxford-AstraZeneca vaccine.

In this case, the gene of the coronavirus' signature spike protein is added to an adenovirus, a common virus that causes colds or flu-like symptoms, which when introduced into the body, delivers the instructions that teach human cells to make the spike protein. That causes the immune system to react by making antibodies to attack the spike protein, so if the person is exposed to COVID-19, the immune system is ready to fight it. It must also be mentioned that the adenovirus is modified so it can enter cells but cannot replicate or cause illness.

How does it fare?

  • Johnson & Johnson vaccine is currently the only vaccine, which is effective after only one dose. Authorities can use this vaccine on people who may be hard to reach or who are otherwise unlikely to get a second dose.
  • Unlike all Indian vaccines, which have to be stored at 2-8 degrees Celsius, the Johnson & Johnson vaccine can be refrigerated for up to three months at normal temperatures. This would allow the government to send these stocks to rural parts of the country where the cold chain may not be well developed.
  • Johnson & Johnson said a study showed the vaccine was 85 percent effective against "severe/critical disease and demonstrated protection against hospitalisation and death".
  • The vaccine was effective across regions studied globally, including in South Africa and Brazil, "where there was a high prevalence of rapidly emerging Beta and Zeta (P.2) variants during the study period", according to the company.
  • The vaccine was 66.3 percent effective in clinical trials (efficacy) at preventing laboratory-confirmed COVID-19 infection in people who received the vaccine and had no evidence of being previously infected.
  • A single dose of the vaccine generated neutralising antibodies against a range of Sars-CoV-2 variants of concern, including against Delta (B.1.617.2), Beta (B.1.351), Gamma (P.1).

Controversies

The vaccine was one of the early candidates to have been cleared by the US Centers for Disease Control, and Prevention (US CDC) and was said to have high efficacy at preventing hospitalisation and death in people. But the vaccine has run into one hurdle after another, notwithstanding the promising trial results.

For instance, On 13 April, the US government paused the administration of the vaccine to investigate a few cases in which people experienced blood clots after receiving the vaccine. All of the cases emerged within two weeks of vaccination. But on 23 April, US health officials lifted the pause after scientific advisers decided the vaccine’s benefits outweigh the risks.

Again, earlier in the month social media users shared posts, which claimed that the vaccine contains aborted fetal DNA as an ingredient, to which the Roman Catholic Archdiocese of New Orleans released a statement calling it "morally compromised". It was later clarified that while the vaccine used lab-replicated fetal cells during its production process, the vaccine itself does not contain any fetal cells.

Besides, as per recent reports, the vaccine increases the risk of Guillain-Barré syndrome during the 42 days following the vaccination. While the vaccine has not been proven to be a causative effect of the disorder, influenza and shingles vaccines have been linked to an increased risk of contracting the syndrome.



from Firstpost India Latest News https://ift.tt/3mgpcnK
FP Staff

Comments

Post a Comment

Popular posts from this blog

Both COVID-19 vaccine doses needed for good protection against B16172 variant

-
It’s been a concerning few weeks in the UK, with the B16172 variant first taking hold and then spreading to become dominant. This more infectious form of the virus, initially identified in India, is what we’re now going to have to live with – unless it is out-competed by another variant in the future. Worryingly, experts had predicted that B16172 might be able to escape some of the effects of vaccines, which if true would threaten to derail the UK’s plans to finish lifting restrictions from the end of June. However, Public Health England (PHE) has looked at the ability of various variants to evade immunity and says that the UK’s vaccines remain effective against the variants circulating, including B16172. On the surface, this looks like good news. But delve a bit deeper, and things get more complicated, says Paul Hunter, professor of medicine at the University of East Anglia. PHE’s research found a little drop-off in protection against B16172 among people who were fully vaccinated.
Read more

New coronavirus variant emerge in India: How should our COVID response change?

-
Image
After genome sequencing of over 10,000 COVID-19 cases in India, researchers have discovered a new variant with two new mutations which may be better at evading the immune system. In 15-20 percent of samples from the Indian state of Maharashtra (the state accounting for 62 percent of cases in the country) a new, double mutation in key areas of the virus has been detected. These are now known as the E484Q and L452R mutations. What makes the variant different? Both these mutations are concerning because they are located in a key portion of the virus – the spike protein – that it uses to penetrate human cells. Spike proteins attach via a “receptor binding domain”, meaning the virus can attach to receptors in our cells. These new mutations include changes to the spike protein that make it a “better fit” for human cells. This means the virus can gain entry more easily and multiply faster. Given what we have seen with other similar mutations , it might also make it harder for our immu
Read more

Aditya L1 Mission: Spacecraft is nearing its final phase, says ISRO chief

-
Aditya L1 spacecraft is nearing its final phase, and manoeuvres to enter the L1 point are expected to be completed by January 7, 2024, according to ISRO Chairman S Somanath. “Aditya is on the way. I think it has reached almost its final phase,” the ISRO chief told PTI on the sidelines of an event organised at VSSC to commemorate the 60th year of the First Sounding Rocket Launch. Aditya L1, India’s first space-based mission to study the Sun, was successfully launched on September 2 from the Satish Dhawan Space Centre (SDSC) in Sriharikota. The spacecraft, after travelling about 1.5 million km from Earth over 125 days, is expected to be placed in a Halo orbit around the Lagrangian point L1, considered closest to the Sun. He said that the last preparations for the spacecraft’s entry into the L1 point are currently underway incrementally.”Possibly by January 7th, the final manoeuvres will be done for entering into the L1 point,” Somanath added. Among other tasks, it will capture and tr
Read more